prednisone has been researched along with Obsessive-Compulsive Disorder in 3 studies
Prednisone: A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.
prednisone : A synthetic glucocorticoid drug that is particularly effective as an immunosuppressant, and affects virtually all of the immune system. Prednisone is a prodrug that is converted by the liver into prednisolone (a beta-hydroxy group instead of the oxo group at position 11), which is the active drug and also a steroid.
Obsessive-Compulsive Disorder: An anxiety disorder characterized by recurrent, persistent obsessions or compulsions. Obsessions are the intrusive ideas, thoughts, or images that are experienced as senseless or repugnant. Compulsions are repetitive and seemingly purposeful behavior which the individual generally recognizes as senseless and from which the individual does not derive pleasure although it may provide a release from tension.
| Excerpt | Relevance | Reference |
|---|---|---|
| " He received six months oral steroid (prednisone) treatment in 20 mg daily dose resulting in symptomatic depression." | 3.72 | Symptomatic depression after long-term steroid treatment: a case report. ( Ros, LT, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (66.67) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ros, LT | 1 |
| Garvey, MA | 1 |
| Swedo, SE | 1 |
| Grabe, HJ | 1 |
| Freyberger, HJ | 1 |
| Maier, W | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Antibiotic Treatment Trial for the PANDAS/PANS Phenotype[NCT01617083] | Phase 2 | 47 participants (Actual) | Interventional | 2012-05-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The CYBOCS is a clinician rated, semi-structured interview for rating the severity of OCD (Scahill, et al., 1997). Total scores range from 0 to 50, with higher scores representing greater severity. The total score is comprised of two subscores, obsessions and compulsions, each with a range of 0-25. (NCT01617083)
Timeframe: Before and after 4 week randomization
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Baseline | After 4 week randomization | |
| Azithromycin | 29.49 | 20.53 |
| Placebo | 28.43 | 23.45 |
The CGI-S scale is a 7-point clinician rating of severity of psychopathology. Severity ratings range from 1 (no illness) to 7 (extremely severe). This instrument has been successfully used in treatment studies (Cook, et al., 2001; Storch, et al., 2007). (NCT01617083)
Timeframe: Before and after 4 week randomization
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Baseline | After 4 week randomization | |
| Azithromycin | 5.24 | 4.06 |
| Placebo | 5.00 | 4.93 |
The Screen for Childhood Anxiety-Related Emotional Disorders (SCARED) is a 41-item parent and participant-completed tool used to measure symptoms of anxiety, including the most common symptoms of panic/somatic, generalized anxiety, separation anxiety, social phobia, and school phobia. Scores range from 0-82, with higher scores indicating more severe symptoms.The child and parent versions of the SCARED have moderate parent-child agreement and good internal consistency, test-retest reliability, and discriminant validity; it is also sensitive to treatment response (Birmaher et al. 1999). The target population for this rating is 8-18 years of age (Birmaher et al. 1997). The parent and child version of the SCARED were administered before and after week 4 randomization. This measure is not validated for use in 4-7 year olds. (NCT01617083)
Timeframe: Before and after 4 week randomization
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Baseline | After 4 week randomization | |
| Azithromycin | 31.82 | 30.88 |
| Placebo | 20.43 | 21.97 |
3 other studies available for prednisone and Obsessive-Compulsive Disorder
| Article | Year |
|---|---|
Symptomatic depression after long-term steroid treatment: a case report.
Topics: Adult; Antidepressive Agents; Depression; Dose-Response Relationship, Drug; Glucocorticoids; Hepatit | 2004 |
Sydenham's chorea. Clinical and therapeutic update.
Topics: Basal Ganglia; Child; Chorea; Female; Humans; Immunoglobulins, Intravenous; Immunotherapy; Male; Obs | 1997 |
Obsessive-compulsive symptom exacerbation following cortisone treatment.
Topics: Adult; Anti-Inflammatory Agents; Colitis; Cortisone; Humans; Male; Obsessive-Compulsive Disorder; Pr | 1998 |